{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:22:57Z","timestamp":1770045777501,"version":"3.49.0"},"reference-count":93,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T00:00:00Z","timestamp":1334016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0001612","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T21:01:39Z","timestamp":1334091699000},"page":"e1612","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant Parasites"],"prefix":"10.1371","volume":"6","author":[{"given":"Rub\u00e9n E.","family":"Varela-M","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janny A.","family":"Villa-Pulgarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Yepes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Modolell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana L.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Muskus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"L\u00f3pez-Ab\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n D.","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faustino","family":"Mollinedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,4,10]]},"reference":[{"key":"ref1","first-page":"1","article-title":"Control of the leishmaniases.","volume":"949","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis.","volume":"366","author":"HW Murray","year":"2005","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1086\/382077","article-title":"Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project.","volume":"38","author":"PJ Hotez","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years.","volume":"21","author":"J Alvar","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis.","volume":"10","author":"J van Griensven","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2174\/092986707780362862","article-title":"Chemotherapy of leishmaniasis: past, present and future.","volume":"14","author":"J Mishra","year":"2007","journal-title":"Curr Med Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis.","volume":"6","author":"S Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"key":"ref8","first-page":"345","article-title":"Visceral leishmaniasis - current therapeutic modalities.","volume":"123","author":"S Sundar","year":"2006","journal-title":"Indian J Med Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/0974-777X.62879","article-title":"Treatment strategies for mucocutaneous leishmaniasis.","volume":"2","author":"E Palumbo","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis.","volume":"19","author":"SL Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00436-008-0943-2","article-title":"Leishmaniasis treatment\u2013a challenge that remains: a review.","volume":"103","author":"DO Santos","year":"2008","journal-title":"Parasitol Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis.","volume":"347","author":"S Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis.","volume":"38","author":"J Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.","volume":"83","author":"I Velez","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by <italic>Leishmania braziliensis<\/italic> in Brazil: a randomized and controlled trial.","volume":"4","author":"PR Machado","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by <italic>Leishmania<\/italic> (<italic>Viannia<\/italic>) <italic>guyanensis<\/italic> in Manaus, Brazil.","volume":"84","author":"A Chrusciak-Talhari","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4269\/ajtmh.2009.81.387","article-title":"Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.","volume":"81","author":"J Soto","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/510588","article-title":"Treatment of Bolivian mucosal leishmaniasis with miltefosine.","volume":"44","author":"J Soto","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.trstmh.2006.02.022","article-title":"Treatment of New World cutaneous leishmaniasis with miltefosine.","volume":"100","author":"J Soto","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7705\/biomedica.v26i1.1514","article-title":"Oral miltefosine to treat leishmaniasis.","volume":"26","author":"J Soto","year":"2006","journal-title":"Biomedica"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.trstmh.2006.02.011","article-title":"Oral miltefosine for the treatment of Indian visceral leishmaniasis.","volume":"100","author":"S Sundar","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.","volume":"196","author":"SK Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","article-title":"Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh.","volume":"85","author":"M Rahman","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis.","volume":"100","author":"H Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","article-title":"Mechanisms of experimental resistance of <italic>Leishmania<\/italic> to miltefosine: Implications for clinical use.","volume":"9","author":"FJ Perez-Victoria","year":"2006","journal-title":"Drug Resist Updat"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","article-title":"Characterisation of <italic>Leishmania donovani<\/italic> promastigotes resistant to hexadecylphosphocholine (miltefosine).","volume":"22","author":"K Seifert","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2007.05.007","article-title":"Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of <italic>Leishmania donovani<\/italic> and persists <italic>in vivo<\/italic>.","volume":"30","author":"K Seifert","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"ref28","first-page":"1320","article-title":"Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH<sub>3<\/sub> (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X<sub>L<\/sub>.","volume":"57","author":"F Mollinedo","year":"1997","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/1078-0432.CCR-09-2456","article-title":"<italic>In vitro<\/italic> and <italic>in vivo<\/italic> selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.","volume":"16","author":"F Mollinedo","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2010.131","article-title":"Lipid raft-targeted therapy in multiple myeloma.","volume":"29","author":"F Mollinedo","year":"2010","journal-title":"Oncogene"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/1389200023337225","article-title":"Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH<sub>3<\/sub> (Edelfosine), a proapoptotic agent in tumor cells.","volume":"3","author":"C Gajate","year":"2002","journal-title":"Curr Drug Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood.V98.13.3860","article-title":"The antitumor ether lipid ET-18-OCH<sub>3<\/sub> induces apoptosis through translocation and capping of Fas\/CD95 into membrane rafts in human leukemic cells.","volume":"98","author":"C Gajate","year":"2001","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.","volume":"109","author":"C Gajate","year":"2007","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.20040213","article-title":"Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.","volume":"200","author":"C Gajate","year":"2004","journal-title":"J Exp Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jac\/38.6.1041","article-title":"The activities of four anticancer alkyllysophospholipids against <italic>Leishmania donovani<\/italic>, <italic>Trypanosoma cruzi<\/italic> and <italic>Trypanosoma brucei<\/italic>.","volume":"38","author":"SL Croft","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0001-706X(01)00197-8","article-title":"Sensitivities of <italic>Leishmania<\/italic> species to hexadecylphosphocholine (miltefosine), ET-18-OCH<sub>3<\/sub> (edelfosine) and amphotericin B.","volume":"81","author":"P Escobar","year":"2002","journal-title":"Acta Trop"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jac\/dkh380","article-title":"Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against <italic>Leishmania amazonensis<\/italic>.","volume":"54","author":"RM Santa-Rita","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00436-006-0408-4","article-title":"<italic>In vitro<\/italic> activity of perifosine: a novel alkylphospholipid against the promastigote stage of <italic>Leishmania<\/italic> species.","volume":"100","author":"MG Cabrera-Serra","year":"2007","journal-title":"Parasitol Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.actatropica.2008.08.005","article-title":"<italic>In vivo<\/italic> activity of perifosine against <italic>Leishmania amazonensis<\/italic>.","volume":"108","author":"MG Cabrera-Serra","year":"2008","journal-title":"Acta Trop"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/AAC.48.8.3010-3015.2004","article-title":"Possible mechanism of miltefosine-mediated death of <italic>Leishmania donovani<\/italic>.","volume":"48","author":"NK Verma","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.48.3.852-859.2004","article-title":"Miltefosine induces apoptosis-like death in <italic>Leishmania donovani<\/italic> promastigotes.","volume":"48","author":"C Paris","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.exppara.2010.05.016","article-title":"<italic>Leishmania tarentolae<\/italic>: utility as an <italic>in vitro<\/italic> model for screening of antileishmanial agents.","volume":"126","author":"VM Taylor","year":"2010","journal-title":"Exp Parasitol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chembiol.2005.08.009","article-title":"DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.","volume":"12","author":"MH David-Cordonnier","year":"2005","journal-title":"Chem Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E","article-title":"Involvement of mitochondria and caspase-3 in ET-18-OCH<sub>3<\/sub>-induced apoptosis of human leukemic cells.","volume":"86","author":"C Gajate","year":"2000","journal-title":"Int J Cancer"},{"key":"ref45","first-page":"2651","article-title":"Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2\u2032,3\u2032,4\u2032-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one: protection by Bcl-2 and Bcl-X<sub>L<\/sub> and cell cycle arrest.","volume":"60","author":"C Gajate","year":"2000","journal-title":"Cancer Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1021\/jm049808a","article-title":"Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells.","volume":"47","author":"E Quesada","year":"2004","journal-title":"J Med Chem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1038\/cddis.2011.41","article-title":"Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.","volume":"2","author":"F Mollinedo","year":"2011","journal-title":"Cell Death Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7705\/biomedica.v24i4.1289","article-title":"Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application.","volume":"24","author":"HH Henao","year":"2004","journal-title":"Biomedica"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-08-1654","article-title":"Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice.","volume":"15","author":"A Estella-Hermoso de Mendoza","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref50","article-title":"Antitumor alkyl-lysophospholipid analogue edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.","author":"C Gajate","year":"2012","journal-title":"Oncogene"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z","article-title":"Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis.","volume":"85","author":"C Gajate","year":"2000","journal-title":"Int J Cancer"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"14833","DOI":"10.1074\/jbc.M511251200","article-title":"Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic <italic>versus<\/italic> solid tumor cells.","volume":"281","author":"T Nieto-Miguel","year":"2006","journal-title":"J Biol Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e5044","DOI":"10.1371\/journal.pone.0005044","article-title":"Involvement of raft aggregates enriched in Fas\/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells.","volume":"4","author":"C Gajate","year":"2009","journal-title":"PLoS ONE"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1021\/jm070595+","article-title":"Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms.","volume":"50","author":"JM Saugar","year":"2007","journal-title":"J Med Chem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1006\/bbrc.1993.1458","article-title":"Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH<sub>3<\/sub>.","volume":"192","author":"F Mollinedo","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/sj.bjp.0701271","article-title":"Dissociation of the effects of the antitumour ether lipid ET-18-OCH<sub>3<\/sub> on cytosolic calcium and on apoptosis.","volume":"121","author":"MT Alonso","year":"1997","journal-title":"Br J Pharmacol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exppara.2009.02.012","article-title":"<italic>Leishmania<\/italic> (<italic>Viannia<\/italic>) <italic>panamensis<\/italic>: an <italic>in vitro<\/italic> assay using the expression of GFP for screening of antileishmanial drug.","volume":"122","author":"MR Varela","year":"2009","journal-title":"Exp Parasitol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.phytochem.2005.01.011","article-title":"Antileishmanial activity and immune modulatory effects of tannins and related compounds on <italic>Leishmania<\/italic> parasitised RAW 264.7 cells.","volume":"66","author":"H Kolodziej","year":"2005","journal-title":"Phytochemistry"},{"key":"ref59","first-page":"131","article-title":"Molecular bases for the anti-parasitic effect of NO.","volume":"9","author":"M Colasanti","year":"2002","journal-title":"Int J Mol Med"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/15216540310001639265","article-title":"The anti-parasitic effects of nitric oxide.","volume":"55","author":"P Ascenzi","year":"2003","journal-title":"IUBMB Life"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF01225687","article-title":"Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U937 cells.","volume":"121","author":"I Eue","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1128\/AAC.36.8.1630","article-title":"Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.","volume":"36","author":"A Kuhlencord","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.42.3.654","article-title":"Short- and long-term efficacy of hexadecylphosphocholine against established <italic>Leishmania infantum<\/italic> infection in BALB\/c mice.","volume":"42","author":"Y Le Fichoux","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1128\/AAC.44.11.3235-3236.2000","article-title":"Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.","volume":"44","author":"HW Murray","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1128\/AAC.00505-09","article-title":"Amiodarone and miltefosine act synergistically against <italic>Leishmania mexicana<\/italic> and can induce parasitological cure in a murine model of cutaneous leishmaniasis.","volume":"53","author":"X Serrano-Martin","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response.","volume":"166","author":"PC Melby","year":"2001","journal-title":"J Immunol"},{"key":"ref67","first-page":"Unit 19 12","article-title":"Animal models for the analysis of immune responses to leishmaniasis.","volume":"19","author":"DL Sacks","year":"2001","journal-title":"Curr Protoc Immunol Chapter"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00034983.1995.11813015","article-title":"Experimental models for leishmaniasis and for testing anti-leishmanial vaccines.","volume":"89","author":"M Hommel","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.1998.59.49","article-title":"Mucosal leishmaniasis due to <italic>Leishmania<\/italic> (<italic>Viannia<\/italic>) <italic>panamensis<\/italic> in Colombia: clinical characteristics.","volume":"59","author":"LE Osorio","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"ref70","first-page":"CD004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis.","author":"U Gonzalez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jac\/dkr485","article-title":"Treatment of <italic>Leishmania donovani<\/italic>-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.","volume":"67","author":"R Gupta","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1517\/14656566.6.16.2821","article-title":"Treatment of visceral leishmaniasis.","volume":"6","author":"S Sundar","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0974-777X.62887","article-title":"Drug resistance in leishmaniasis.","volume":"2","author":"J Chakravarty","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1086\/507710","article-title":"American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?","volume":"194","author":"V Yardley","year":"2006","journal-title":"J Infect Dis"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1086\/518041","article-title":"Influence of <italic>Leishmania<\/italic> (<italic>Viannia<\/italic>) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.","volume":"195","author":"J Arevalo","year":"2007","journal-title":"J Infect Dis"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/AAC.43.2.278","article-title":"Stage-specific activity of pentavalent antimony against <italic>Leishmania donovani<\/italic> axenic amastigotes.","volume":"43","author":"M Ephros","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1128\/AAC.42.8.1990","article-title":"Sensitivity of <italic>Leishmania viannia panamensis<\/italic> to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes.","volume":"42","author":"A Lucumi","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2307\/3285647","article-title":"Sensitivity to Glucantime of <italic>Leishmania viannia<\/italic> isolated from patients prior to treatment.","volume":"85","author":"SM Robledo","year":"1999","journal-title":"J Parasitol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1645\/GE-3347","article-title":"Inhibition of <italic>Leishmania donovani<\/italic> promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents.","volume":"90","author":"J Walker","year":"2004","journal-title":"J Parasitol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00436-007-0638-0","article-title":"Glucantime-resistant <italic>Leishmania tropica<\/italic> isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.","volume":"101","author":"R Hadighi","year":"2007","journal-title":"Parasitol Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00436-011-2599-6","article-title":"The effect of verapamil on <italic>in vitro<\/italic> susceptibility of promastigote and amastigote stages of <italic>Leishmania tropica<\/italic> to meglumine antimoniate.","volume":"110","author":"A Shokri","year":"2012","journal-title":"Parasitol Res"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4269\/ajtmh.2009.80.580","article-title":"Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.","volume":"80","author":"BD Pandey","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4269\/ajtmh.2006.75.1074","article-title":"Relapse of new world diffuse cutaneous leishmaniasis caused by <italic>Leishmania<\/italic> (<italic>Leishmania<\/italic>) <italic>mexicana<\/italic> after miltefosine treatment.","volume":"75","author":"M Calvopina","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1365-2133.2007.07872.x","article-title":"Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.","volume":"156","author":"O Zerpa","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00365540701466215","article-title":"Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.","volume":"40","author":"J Troya","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/425359","article-title":"Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.","volume":"39","author":"H Sindermann","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/jpet.108.148254","article-title":"Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis.","volume":"329","author":"F Mollinedo","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"34528","DOI":"10.1074\/jbc.M110.125302","article-title":"Selective fusion of azurophilic granules with <italic>Leishmania<\/italic>-containing phagosomes in human neutrophils.","volume":"285","author":"F Mollinedo","year":"2010","journal-title":"J Biol Chem"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.4049\/jimmunol.173.11.6521","article-title":"Cutting edge: neutrophil granulocyte serves as a vector for <italic>Leishmania<\/italic> entry into macrophages.","volume":"173","author":"G van Zandbergen","year":"2004","journal-title":"J Immunol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"e844","DOI":"10.1371\/journal.pntd.0000844","article-title":"Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.","volume":"4","author":"G Tasew","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"854","DOI":"10.4269\/ajtmh.2007.77.854","article-title":"Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease.","volume":"77","author":"G Bomfim","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0014-4894(83)90035-8","article-title":"<italic>Leishmania<\/italic> species: comparative ultrastructure of experimental nodules and diffuse human cutaneous lesions in American leishmaniases.","volume":"55","author":"A Bretana","year":"1983","journal-title":"Exp Parasitol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.4049\/jimmunol.0713598","article-title":"IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice.","volume":"182","author":"S Lopez Kostka","year":"2009","journal-title":"J Immunol"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0001612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:49:02Z","timestamp":1588974542000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0001612"}},"subtitle":[],"editor":[{"given":"Jayne","family":"Raper","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,4,10]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0001612","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,10]]}}}